Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the ...

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax expects to be ready for the commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this fall in partnership with Sanofi, pending strain recommendation at the FDA ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.

The Food and Drug Administration has approved Novavax's COVID-19 vaccine but with unusual restrictions. Novavax makes the nation's only traditional protein-based coronavirus vaccine and while it ...

The FDA has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.